What is the translation of " RANDOMISED STUDY " in Slovenian?

• randomizirana študija
• randomizirani študiji
• randomizirano študijo

Examples of using Randomised study in English and their translations into Slovenian

COMFORT-II was an open-label, randomised study in 219 patients.
COMFORT-II je bila odprta, randomizirana študija z 219 bolniki.

Another randomised study included 66 patients on tacrolimus versus 67 patients on ciclosporin.
Druga randomizirana študija je primerjala 66 bolnikov na takrolimusu s 67 bolniki na ciklosporinu.

Study ENB-009-10 was an open-label, randomised study.
Študija ENB-009-10 je bila odprta, randomizirana študija.

Our next step will be a randomised study comparing the results of partial and conventional uterine fibroid embolization.”.
Naš naslednji korak bo randomizirana študija, ki bo primerjala rezultate delnih in konvencionalnih UFE.".

Patients with serum creatininegt; 1.5 x Upper Limit of the Normal range(ULN) were excluded from the randomised study.
Bolniki s koncentracijo kreatinina v serumugt; 1,5 x večjo od zgornje meje normalne vrednosti(ULN) so bili izključeni iz randomizirane študije.

Double-blind, placebo-controlled, randomised study of single dose effects of ADAPT-232 on cognitive functions.
Dvojno slepa, s placebom kontrolirana, randomizirana študija učinkov posameznih odmerkov ADAPT-232 na kognitivne funkcije.

The clinical safety of OZURDEX in patients with inflammation of the posterior segment of the eye presenting as non-infectious uveitis, has been assessed in a single, multicentre, masked, randomised study.
Klinično varnost zdravila OZURDEX pri bolnikih z vnetjem posteriornega dela očesa, ki se kaže kot nenalezljivi uveitis, so ocenili v enojni, multicentrični, slepi, randomizirani študiji.

Aslanyan G et al. Double-blind, placebo-controlled, randomised study of single dose effects of ADAPT-232 on cognitive functions.
Dvojno slepa, s placebom kontrolirana, randomizirana študija učinkov posameznih odmerkov ADAPT-232 na kognitivne funkcije.

A phase III randomised study of Caelyx versus doxorubicin in patients with metastatic breast cancer was completed in 509 patients.
Randomizirano raziskavo faze III, v kateri so zdravilo Caelyx primerjali s standardnim doksorubicinom pri bolnikih z metastatskim rakom dojk, je zaključilo 509 bolnikov.

None of the patients treated in the osteosarcoma studies were 65 years or older and in the phase III randomised study, only patients up to the age of 30 years were included.
Nobeden od bolnikov, ki so se zdravili v okviru študij o osteosarkomu, ni bil star 65 let ali več, v randomizirano študijo III. faze pa so bili vključeni le bolniki, mlajši od 30 let.

One multicentre, double-masked, placebo-controlled, randomised study(BPD OCR 003 PM[VIP- PM]) was conducted in patients with subfoveal choroidal neovascularisation caused by pathological myopia.
Ena multicentrična dvojno maskirana s placebom kontrolirana randomizirana študija(BPD OCR 003 PM[VIP-PM]) je bila opravljena pri bolnikih s subfovealno horioidalno neovaskularizacijo, ki jo je povzročila bolezenska kratkovidnost.

The difference in bioavailability was less marked upon steady-state administration to renal transplant recipients, and therapeutic equivalence has been demonstrated in randomised study of 477 patients.
Razlika v biološki uporabnosti je manj izrazita pri bolnikih s presajeno ledvico v stanju dinamičnega ravnovesja, terapevtsko ekvivalentnost pa so ugotovili v randomizirani študiji pri 477 bolnikih.

This was a double-blind, placebo-controlled, randomised study in pre-term or term neonates(gestational age 36- 42 weeks) with PPHN.
To je bila dvojno-slepa, s placebom nadzorovana, randomizirana študija pri nedonošenih in donošenih novorojenčkih(gestacijska starost 36- 42 tednov) s PPHN.

Using the 17-segment model, the number of segments showing a reversible perfusion defect was calculated for the initial adenosine study and for the randomised study obtained using Rapiscan or adenosine.
Na modelu s 17 segmenti je bilo število segmentov, ki kažejo reverzibilno perfuzijsko okvaro, izračunano za začetno študijo z adenozinom in za randomizirano študijo z uporabo zdravila Rapiscan ali adenozina.

The clinical efficacy of OZURDEX has been assessed in a single, multicentre, masked, randomised study for the treatment of non-infectious ocular inflammation of the posterior segment in patients with uveitis.
Klinično učinkovitost zdravila OZURDEX so ocenili v enojni, multicentrični, slepi, randomizirani študiji za zdravljenje nenalezljivega vnetja posteriornega dela očesa pri bolnikih z uveitisom.

This randomised study compared the combination of cetuximab and radiation therapy(211 patients) with radiation therapy alone(213 patients) in patients with locally advanced squamous cell cancer of the head and neck.
V tej randomizirani študiji so primerjali kombinacijo cetuksimaba in radioterapije(211 bolnikov) z radioterapijo v monoterapiji(213 bolnikov) pri bolnikih z lokalno napredovalim rakom skvamoznih celic glave in vratu.

It is likely that these adverse reactions also occurred in the large randomised study, but they were not recorded because only serious and life- threatening adverse reactions were collected in that study..
Ti neželeni učinki so se verjetno pojavili tudi v obsežni randomizirani študiji, vendar pa niso bili zabeleženi, saj so v tej študiji zbirali podatke samo o hudih in življenjsko nevarnih neželenih učinkih.

In randomised study CC-4047-MM-003, 302 patients with relapsed and refractory multiple myeloma were exposed to 4 mg pomalidomide administered once daily for 21 days of each 28 day cycle in combination with a weekly low dose of dexamethasone.
V randomizirani študiji(CC-4047-MM-003) sta bila 302 bolnika s ponovljenim in na zdravljenje odpornim diseminiranim plazmocitomom izpostavljena 4 mg pomalidomida, danim enkrat na dan za 21 dni vsakega 28-dnevnega cikla v kombinaciji z nizkim tedenskim odmerkom deksametazona.

Submission of the final clinical study report for study 3066K1-4438-WW, a randomised study comparing 2 intravenous temsirolimus regimens in patients with relapsed, refractory Mantle Cell Lymphoma.
Predložitev končnega poročila klinične študije za študijo 3066K1-4438-WW, randomizirano študijo, v kateri se primerjata 2 intravenski shemi temsirolimusa pri bolnikih z recidivnim, proti zdravljenju odpornim limfomom plaščnih celic.

A randomised study assessed the clinical efficacy response rate in DMARD-naïve patients(n= 121) with early RA, who received either 20 mg or 100 mg of leflunomide in two parallel groups during the initial three day double blind period.
Randomizirana študija je ocenila delež odzivnosti pri bolnikih(n= 121), ki še niso bili zdravljeni z imunomodulirajočimi protirevmatičnimi zdravili, so imeli zgoden RA in so med uvodnim tridnevnim dvojno slepim obdobjem prejemali bodisi 20 mg bodisi 100 mg leflunomida v dveh vzporednih skupinah.

Treatment of ST segment elevation myocardial infarction(STEMI) OASIS 6 was a double blind, randomised study assessing the safety and efficacy of fondaparinux 2.5 mg once daily, versus usual care placebo(47%) or UFH(53%) in approximately 12,000 patients with STEMI.
Zdravljenje miokardnega infarkta z dvigom segmenta ST(STEMI) OASIS 6 je bila dvojno slepa, randomizirana študija, ki je vrednotila varnost in učinkovitost fondaparinuksa v odmerku 2, 5 mg enkrat na dan v primerjavi z običajnim zdravljenjem(placebo(47%) ali UFH (53%)) pri približno 12. 000 bolnikih s STEMI.

This randomised study in patients with metastatic colorectal cancer who had received initial combination treatment with oxaliplatin plus fluoropyrimidine for metastatic disease compared the combination of cetuximab and irinotecan(648 patients) with irinotecan alone(650 patients).
V tej randomizirani študiji so pri bolnikih z metastatskim kolorektalnim rakom, ki so se na začetku zdravljenja metastatske bolezni zdravili s kombinacijo oksaliplatina in fluoropirimidina, primerjali kombinacijo cetuksimaba in irinotekana(648 bolnikov) s samostojnim iritonekanom(650 bolnikov).

A prospective, placebo-controlled, randomised study in 26 patients with Lambert-Eaton myasthenic syndrome(LEMS) reported clinical efficacy for amifampridine at the standard recommended maximum dose of 60 mg/day(Sanders et al 2000).
V prospektivni, s placebom nadzorovani randomizirani študiji pri 26 bolnikih z Lambert-Eatonovim miastenijskim sindromom(LEMS) so poročali o klinični učinkovitosti amifampridina pri standardnem priporočenem največjem odmerku 60 mg/dan(Sandersetal 2000).

This randomised study in patients with metastatic colorectal cancer after failure of irinotecan-based treatment for metastatic disease as the last treatment before study entry compared the combination of cetuximab and irinotecan(218 patients) with cetuximab monotherapy(111 patients).
V tej randomizirani študiji so pri bolnikih z metastatskim kolorektalnim rakom po neuspešnem zdravljenju metastatske bolezni z irinotekanom kot zadnjem zdravljenjem pred vstopom v študijo primerjali kombinacijo cetuksimaba in irinotekana(218 bolnikov) s samostojnim cetuksimabom(111 bolnikov).

ACTG 5202 study was a, multi-centre, comparative, randomised study of double-blind abacavir/lamivudine or emtricitabine/tenofovir in combination with open-label efavirenz or atazanavir/ritonavir in treatment-naïve HIV-1 infected patients.
Študija ACTG 5202 je bila multicentrična, primerjalna, randomizirana študija z dvojno slepo uporabo abakavirja/lamivudina ali emtricitabina/tenofovirja v kombinaciji odprte uporabe efavirenza ali atazanavirja/ritonavirja pri bolnikih, okuženih s HIV-1, ki še niso prejemali zdravljenja.

This randomised study in patients with metastatic colorectal cancer who had not received prior treatment for metastatic disease compared the combination of cetuximab and oxaliplatin plus infusional 5-fluorouracil/ folinic acid(5-FU/ FA)(169 patients) to the same chemotherapy alone(168 patients).
Ta randomizirana študija pri bolnikih z metastatskim kolorektalnim rakom, ki še niso bili zdravljeni zaradii metastatske bolezni, je primerjala kombinacijo cetuksimaba in oksaliplatina ter infudiranega 5- fluorouracila/ folinske kisline(5- FU/ FA)(169 bolnikov) z enako kemoterapijo v monoterapiji(168 bolnikov).

To perform a post-authorisation randomised study in patients with neovascular(wet) AMD with the primary objective of comparing the standard regime of injections every 8 weeks with a reactive regimen based on visual and anatomic outcomes, based on a CHMP approved protocol.
Izvesti post-autorizacijsko randomizirano študijo pri bolnikih z neovaskularno(vlažno) AMD, katere primarni cilj bo primerjati standardni režim injiciranja vsakih 8 tednov z režimom glede na oceno ostrine vida in anatomski izgled rumene pege, v skladu s protokolom, odobrenim s strani CHMP.

A three-arm randomised study investigating the combination of everolimus with exemestane versus everolimus alone versus capecitabine in patients with oestrogen-receptor positive metastatic breast cancer after recurrence or progression on letrozole or anastrozole based on a CHMP approved protocol.
Randomizirana študija s tremi skupnami za primerjavo kombinacije everolimusa z eksemestanom, samega everolimusa in kapecitabina pri bolnicah z metastatskim rakom dojke, pozitivnim na estrogenske receptorje, po ponovitvi ali napredovanju bolezni ob zdravljenju z letrozolom ali anastrozolom po protokolu, ki ga je odobril odbor CHMP.